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Background. In sub-Saharan Africa, 20%–25% of people starting antiretroviral therapy (ART) have severe immunosuppression; 
approximately 10% die within 3 months. In the Reduction of EArly mortaLITY (REALITY) randomized trial, a broad enhanced 
anti-infection prophylaxis bundle reduced mortality vs cotrimoxazole. We investigate the contribution and timing of different causes 
of mortality/morbidity.
Methods. Participants started ART with a CD4 count <100 cells/µL; enhanced prophylaxis comprised cotrimoxazole plus 12 
weeks of isoniazid + fluconazole, single-dose albendazole, and 5 days of azithromycin. A blinded committee adjudicated events and 
causes of death as (non–mutually exclusively) tuberculosis, cryptococcosis, severe bacterial infection (SBI), other potentially azith-
romycin-responsive infections, other events, and unknown.
Results. Median pre-ART CD4 count was 37 cells/µL. Among 1805 participants, 225 (12.7%) died by week 48. Fatal/nonfatal 
events occurred early (median 4 weeks); rates then declined exponentially. One hundred fifty-four deaths had single and 71 had 
multiple causes, including tuberculosis in 4.5% participants, cryptococcosis in 1.1%, SBI in 1.9%, other potentially azithromycin-re-
sponsive infections in 1.3%, other events in 3.6%, and unknown in 5.0%. Enhanced prophylaxis reduced deaths from cryptococcosis 
and unknown causes (P < .05) but not tuberculosis, SBI, potentially azithromycin-responsive infections, or other causes (P > .3); and 
reduced nonfatal/fatal tuberculosis and cryptococcosis (P < .05), but not SBI, other potentially azithromycin-responsive infections, 
or other events (P > .2).
Conclusions. Enhanced prophylaxis reduced mortality from cryptococcosis and unknown causes and nonfatal tuberculosis 
and cryptococcosis. High early incidence of fatal/nonfatal events highlights the need for starting enhanced-prophylaxis with ART 
in advanced disease.
Clinical Trials Registration. ISRCTN43622374.
Keywords. HIV; Africa; antiretroviral therapy; mortality; morbidity.
In sub-Saharan Africa, 20%–25% of human immunodeficiency 
virus (HIV)–infected individuals starting antiretroviral therapy 
(ART) have a CD4 count <100 cells/µL [1]; approximately 10% 
die within 3 months [2–5]. In the recently reported Reduction of 
EArly mortaLITY in HIV-infected adults and children starting 
ART (REALITY) randomized trial, a broad enhanced anti-infec-
tion prophylaxis bundle reduced all-cause mortality vs cotrimoxa-
zole alone in adults and children aged ≥5 years initiating ART with 
a CD4 count <100 cells/µL [6]. Here, we investigate in detail the 
relative contribution of different causes of mortality and morbidity. 
In particular, we investigate the timing of different causes of mor-
tality/morbidity, as most studies of early mortality have analyzed 
causes of death over fixed time scales after starting ART [5] and not 
reported changes in cause-specific mortality rates over time after 
starting ART.
METHODS
The REALITY trial (ISRCTN43622374) recruited 1805 HIV-
infected ART-naive adults and children ≥5  years (98% aged 
≥13 years) from Zimbabwe, Uganda, Malawi, and Kenya with 
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a CD4 count <100 cells/µL. In brief, participants were rand-
omized 1:1 to enhanced prophylaxis vs standard prophylaxis 
(cotrimoxazole) [6], together with World Health Organization 
(WHO)–recommended combination ART comprising 2 nucle-
oside reverse transcriptase inhibitors (NRTIs) (tenofovir dis-
oproxil fumarate + emtricitabine or zidovudine + lamivudine 
in adults) and 1 nonnucleoside reverse transcriptase inhibitor 
(NNRTI) (predominantly efavirenz). Enhanced prophylaxis 
comprised single-dose albendazole, 5 days of azithromycin, 12 
weeks of fluconazole (100 mg), and 12 weeks of fixed-dose com-
bination of cotrimoxazole (800/160  mg)/isoniazid (300  mg)/
pyridoxine (25  mg) once daily. For children aged 5–12  years, 
doses were halved (except albendazole). Isoniazid/pyridoxine 
use post–week 12 depended on national isoniazid preventive 
therapy guidelines. Participants already receiving or needing 
antimicrobial treatment or prophylaxis received it outside the 
randomized design, and received other prophylaxis according 
to randomization. Participants were factorially randomized 
1:1 to 12 weeks of raltegravir vs no raltegravir, and 12 weeks of 
ready-to-use supplementary food vs standard nutritional sup-
port; neither affected mortality (previously reported in [7, 8]). 
Adults and children’s guardians gave written informed con-
sent; older children gave additional assent following national 
guidelines. REALITY was approved by ethics committees in 
Zimbabwe, Uganda, Malawi, Kenya, and the United Kingdom.
Clinical events occurring through 48 weeks were ascertained 
at trial visits (see Supplementary Methods). Adverse events (AEs) 
were graded following standard tables [9, 10]. Serious adverse events 
(SAEs) were those leading to death, being life-threatening, causing/
prolonging hospitalization, or causing permanent disability, or were 
other medical conditions with a risk of 1 of these categories.
Endpoint Review
An endpoint review committee (ERC) (majority independ-
ent members) adjudicated causes of death and nonfatal events 
(grade 3/4 AEs, SAEs, WHO stage 3/4 events) using clinical 
narratives written by the treating physician and reviewed by the 
center’s principal investigator. Events were adjudicated against 
protocol-defined criteria and grading tables [9, 10] and blinded 
to interventional drugs received (prophylaxis, raltegravir, and 
supplementary food). Events were also assessed for compatibil-
ity with immune reconstitution inflammatory syndrome (IRIS). 
Events were considered IRIS compatible if there was atypical or 
exaggerated presentation of an opportunistic infection or tumor 
soon after ART initiation. Viral loads (VL) were only measured 
retrospectively on stored plasma, so were not available contem-
poraneously; the earliest CD4 count was done at week 4 and 
thus was not available for events before this. As access to diag-
nostic testing was limited, previously published definitions [11, 
12] were used but in modified form; the ERC relied heavily on 
the description of the clinical presentation and any radiology/
microbiology/histology provided by site, and the timing of the 
presentation and its evolution in relation to ART initiation. An 
unblinded clinical reviewer at the coordinating center reviewed 
grade 3/4 laboratory (nonclinical) events.
Statistical Analysis
The ERC classified causes of death and events, blinded to ran-
domized group, as related to tuberculosis, cryptococcosis, 
severe bacterial infection (SBI; including pneumonia/menin-
gitis), other infections potentially responsive to azithromycin 
(denoted “potentially azithromycin-responsive infections”: 
diarrhea, malaria, encephalitis, cerebral toxoplasmosis, or other 
indeterminate severe cerebral events, intracerebral lesions, 
septic abortion), other events (either noninfectious or infec-
tions not responsive to azithromycin), and unknown (deaths 
only). Indeterminate severe cerebral events and intracerebral 
lesions were considered azithromycin responsive as these could 
potentially be toxoplasmosis. Categories were not mutually 
exclusive.
Analyses were conducted overall and, as enhanced prophy-
laxis reduced mortality, considering effects of enhanced proph-
ylaxis vs cotrimoxazole alone. Analyses of causes of death, and 
first fatal/nonfatal events (including grade 3/4 AE, SAE, and 
WHO stage 3/4 events) used competing risks methods [13]. All 
follow-up from randomization to the earliest of 48 weeks, or last 
contact with clinic staff, was included. To estimate continuously 
varying cause-specific rates, we used flexible parametric models 
(see details in Supplementary Methods). Event rates were esti-
mated to rise for at least 7 days after randomization, plausibly 
reflecting exclusion of patients without capacity to consent due 
to severe comorbidities, leading to few deaths being observed 
during the first few days after randomization. Therefore, while 
analysis included all follow-up, interpretation of results focused 
on follow-up post–7 days (Supplementary Methods). Finally, as 
enhanced prophylaxis significantly reduced death from crypto-
coccosis and from unknown causes [6], predictors of these 
deaths were identified using competing risks methods [13] 
(details in Supplementary Methods).
All analyses were performed using Stata 15.1 software 
(StataCorp, College Station, Texas). P values are 2-sided.
RESULTS
A total of 1805 participants initiated ART between June 2013 
and April 2015. Median age was 36 years, median CD4 count 
was 37 cells/µL, and 1326 of 1792 (74.0%) had HIV VL ≥100 000 
copies/mL (Table  1). Despite profound immunosuppression, 
854 (47.3%) had only WHO stage 1/2 disease [6].
Deaths
Of the 225 deaths by 48 weeks on ART, 154 (68.4%) were 
assigned to a single category and 71 (31.6%) to multiple catego-
ries. Overall, the most common cause of death (non–mutually 
exclusive) was unknown (n = 88 participants [5.0% cumulative 
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incidence]; many died at home), then tuberculosis (n  =  80 
[4.5%]), other events (n = 63 [3.6%]), SBI (n = 33 [1.9%]), other 
potentially azithromycin-responsive infections (n = 23 [1.3%]), 
and cryptococcosis (n = 20 [1.1%]). Sixty-seven (29.8%) deaths 
were adjudicated as compatible with IRIS. Enhanced prophy-
laxis reduced all-cause mortality by 24 weeks by 27% (hazard 
ratio, 0.73; 95% confidence interval, .55–.98) log-rank P = .03), 
which was maintained through 48 weeks (see Figure 2B in [6]). 
Overall, enhanced prophylaxis reduced deaths from unknown 
causes (3.8% vs 6.1% standard prophylaxis, competing risks 
P =  .03) and from cryptococcosis (0.6% vs 1.8%, respectively; 
P = .03); with a similar trend in IRIS-compatible deaths (2.9% 
vs 4.6%, respectively; P  =  .06) (Supplementary Figure  1). 
There was no evidence that enhanced prophylaxis affected 
deaths from tuberculosis (P  =  .34), SBI (P  =  .90), potentially 
azithromycin-responsive infections (P = .31), and other events 
(P = .66). However, regardless of prophylaxis received, mortality 
rates were highest during the first 4 weeks on ART, dropping 
substantially through week 8, before dropping further through 
weeks 24 and 48 (Figure 1; Supplementary Table 1).
Fatal and Nonfatal Events
By 48 weeks on ART, 963 first fatal or nonfatal (grade 3/4 AE, 
SAE, WHO stage 3/4) events of each category occurred in 674 
(37.3%) participants. The most common were other events 
(n  =  479 participants [27.0%]) (Supplementary Table  2), fol-
lowed by tuberculosis (n = 195 [10.9%]), SBIs (n = 91 [5.1%]), 
other potentially azithromycin-responsive infections (n  =  65 
Table 1. Characteristics at Enrollment
Factor
Standard Prophylaxis 
(n = 899)
Enhanced Prophylaxis 
(n = 906)
All 
(N = 1805)
Country Kenya 174 (19.4) 177 (19.5) 351 (19.4)
Malawi 128 (14.2) 127 (14.0) 255 (14.1)
Uganda 313 (34.8) 317 (35.0) 630 (34.9)
Zimbabwe 284 (31.6) 285 (31.5) 569 (31.5)
Male sex 484 (53.8) 477 (52.6) 961 (53.2)
Age, y 36 (30–42) [range, 5–78] 36 (29–42) [range, 6–71] 36 (29–42) [range, 5–78]
Age 5–17 y 33 (3.7) 39 (4.3) 72 (4.0)
WHO stage 1 153 (17.0) 147 (16.2) 300 (16.6)
2 265 (29.5) 289 (31.9) 554 (30.7)
3 349 (38.8) 342 (37.7) 691 (38.3)
4 132 (14.7) 128 (14.1) 260 (14.4)
CD4 counta, cells/µL 36 (16–60) 38 (16–64) 37 (16–63)
CD8 count, cells/µL (n = 1693) 473 (302–734) 497 (317–721) 482 (308–726)
HIV viral load, copies/mL (n = 1792) 250 000 (92 460–544 240) 246 130 (97 620–654 160) 249 770 (95 540–604 960)
HIV viral load ≥100 000 copies/mL 655/893 (73.3) 671/899 (74.6) 1326/1792 (74.0)
BMI, kg/m2 (n = 1797) 19.3 (17.4–21.5) 19.1 (17.1–21.3) 19.2 (17.2–21.4)
Hemoglobin, g/dL (n = 1800) 11.2 (9.6–12.7) 11.1 (9.5–12.8) 11.2 (9.6–12.7)
Creatinine clearanceb, mL/min (n = 1793) 97.1 (77.8–120.1) 97.3 (76.6–121.9) 97.3 (77.3–121.1)
Albumin, g/L (n = 1751) 35 (30–40) 35 (30–40) 35 (30–40)
Bilirubin, µmol/L (n = 1768) 6.0 (3.9–8.4) 6.0 (3.8–9.0) 6.0 (3.8–8.9)
WBC count, 109/L (n = 1800) 3.6 (2.7–4.7) 3.5 (2.7–4.7) 3.5 (2.7–4.7)
Lymphocyte count, 109/L (n = 1790) 0.9 (0.7–1.3) 1.0 (0.7–1.4) 1.0 (0.7–1.4)
Neutrophil count, 109/L (n = 1783) 1.8 (1.2–2.6) 1.7 (1.2–2.5) 1.7 (1.2–2.6)
Platelet count, 109/L (n = 1789) 252 (184–333) 252 (183–352) 252 (183–342)
Water source (n = 1761)
 Protected well 327 (37.3) 296 (33.5) 623 (35.4)
 Domestic tap: private standpipe 246 (28.1) 258 (29.2) 504 (28.6)
 Domestic tap: communal standpipe 98 (11.2) 89 (10.1) 187 (10.6)
 Communal tap 119 (13.6) 136 (15.4) 255 (14.5)
 Lake/river/stream 32 (3.6) 41 (4.6) 73 (4.1)
 Unprotected well 55 (6.3) 64 (7.2) 119 (6.8)
Household toilet type (n = 1794)
 Pit/latrine 635 (70.6) 616 (68.8) 1251 (69.7)
 Flush 264 (29.4) 279 (31.2) 543 (30.3)
Data are presented as No. (%) or median (interquartile range).
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; WBC, white blood cell; WHO, World Health Organization.
aMean of screening and enrollment values. Eligibility required screening CD4 count to be <100 cells/µL, so baseline could be ≥100 cells/µL depending on the CD4 at enrollment.
bEstimated using Cockcroft-Gault, normalized to 1.73 m2.
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[3.6%]), and cryptococcosis (n  =  44 [2.5%]). One hundred 
seventy-five (9.8%) participants had IRIS-compatible events. 
Enhanced prophylaxis reduced tuberculosis (8.9% vs 13.0% 
standard prophylaxis; P = .007), cryptococcosis (1.7% vs 3.3%, 
respectively; P  =  .03), and IRIS-compatible events (7.5% vs 
12.2%, respectively; P = .001) (Supplementary Figure 2), but not 
SBIs (P  =  .26), potentially azithromycin-responsive infections 
(P = .34), or other events (P = .81). Although occurring at much 
higher rates (Figure 2), similarly to deaths, first fatal or nonfa-
tal events predominantly occurred very shortly after ART ini-
tiation (median, 4.0 weeks; interquartile range [IQR], 2.0–11.7 
weeks), even for the large group of other events which included 
Figure 1. Rates (per 100 person-years [PY]) of fatal events over time from antiretroviral therapy (ART) initiation due to tuberculosis (A), cryptococcosis (B), severe bacterial 
infections (C), potentially azithromycin-responsive infections (D), other events (E), unknown deaths (F), and immune reconstitution inflammatory syndrome (IRIS)–compatible 
deaths (G). Vertical dashes show times when events occurred; length proportional to number of events (≥10 shown as 10). Order as legend (standard, enhanced). All-cause 
mortality shown in Supplementary Figure 4A of [6].
S136 • CID 2018:66 (Suppl 2) • Post et al
probable noninfectious events and those not traditionally con-
sidered HIV-related (Supplementary Table 2). Rates for all types 
of events declined exponentially from the third week on ART.
At 48 weeks post–ART initiation, rates of fatal/nonfatal 
events were lowest (<1/100 person-years [PY] for cryptococ-
cosis; Supplementary Table 1). Rates were moderate (1–5/100 
PY) for tuberculosis, SBIs, and other potentially azithromy-
cin-responsive infections. Rates were highest (>5/100 PY) for 
other events. Death rates were highest (1–5/100 PY) for deaths 
from tuberculosis, SBIs, and unknown causes.
Predictors of Deaths From Cryptococcosis and Unknown Causes
Given the impact of enhanced prophylaxis on deaths from 
cryptococcosis and unknown causes, we considered whether 
predictors of these 2 categories of death were similar, suggest-
ing unascertained cryptococcal disease could be driving these 
Figure 2. Rates (per 100 person-years [PY]) of combined fatal plus nonfatal events over time from antiretroviral therapy (ART) initiation: tuberculosis (A), cryptococcosis 
(B), severe bacterial infections (C), potentially azithromycin-responsive infections (D), other events (E), and immune reconstitution inflammatory syndrome (IRIS)–compatible 
events (F). Vertical dashes show times when events occurred; length proportional to number of events (≥10 shown as 10). Order as legend (standard, enhanced).
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effects. Deaths from cryptococcosis were more common in 
standard prophylaxis (P = .03) and participants with lower base-
line CD4 count (P = .02) or self-reported vomiting (P = .005) 
(Supplementary Table  3). Deaths from unknown causes were 
more common in participants administered standard prophy-
laxis (P = .03); those with lower baseline CD4 count (P = .05), 
creatinine clearance (P < .001), or albumin (P = .01); higher bili-
rubin (P = .05); without previous healthcare contact (P = .04); 
or with wasting/severe weight loss (P  =  .02), participant-re-
ported fever (P = .08), or problems with mobility (P = .05) or 
self-care (P = .05). There was no effect of water source or house-
hold toilet type on either cause of death (P > .3).
Last Postbaseline VL and CD4 Count Before Fatal and Nonfatal 
Events of Each Cause
Considering the 1716 participants alive and in follow-up at 
week 4, median last postbaseline VL before death was 95 (IQR, 
<50–522) copies/mL (Supplementary Table  4), with relatively 
little variation between causes, suggesting excellent VL re-
sponse, given high values pre-ART. However, median CD4 
count was only 59 (IQR, 32–101) cells/µL, also with little vari-
ation between causes, demonstrating that most remained se-
verely immunocompromised. Results were similar for nonfatal 
events (Supplementary Table 4).
DISCUSSION
In the REALITY trial of patients starting ART with severe im-
munosuppression in sub-Saharan Africa, morbidity/mortality 
rates were high in the first month after starting ART, regardless 
of type of event, and dropped exponentially thereafter. However, 
even within a randomized trial with intensive follow-up, struc-
tured clinical narratives, and independent endpoint review, 
causes of death were difficult to ascertain and the commonest 
category was unknown. Furthermore, multiple causes were 
identified in almost one-third of deaths, highlighting the com-
plexity of clinical presentations in patients starting ART with 
advanced immunosuppression.
REALITY showed that enhanced prophylaxis reduces mor-
tality by 27% [6], due to reductions in deaths from cryptococ-
cosis and unknown causes, but not from tuberculosis or severe, 
but mainly presumptive, bacterial infections. Nonfatal tubercu-
losis events were, however, significantly reduced, leaving only 
azithromycin and albendazole, of the 5 different antimicrobial 
agents, without clear benefit. We therefore explored whether 
deaths due to infections potentially responsive to azithromycin 
(predominantly toxoplasmosis, diarrhea/gastroenteritis, and 
malaria) were reduced by enhanced prophylaxis, but found no 
evidence of this. The apparent lack of impact on bacterial infec-
tions raises questions about using 5 days of azithromycin within 
enhanced prophylaxis [14], particularly given concerns about 
antimicrobial resistance. However, it is not possible to exclude 
azithromycin on the basis of these findings alone. For example, 
29.5% of deaths from unknown causes occurred within the first 
4 weeks after ART initiation and many occurred at home, mak-
ing it difficult to exclude the possibility that azithromycin had 
a role in reducing undiagnosed SBIs causing these early deaths. 
Alternatively, azithromycin may have been ineffective against 
the most common causes of bacterial infections in this popula-
tion, for example, due to already high rates of antimicrobial re-
sistance [15]. To explore whether deaths from unknown causes 
could have been caused by cryptococcosis, we identified pre-
dictors of mortality from these causes. Although both deaths 
from cryptococcosis and unknown causes were predicted by 
low CD4 count, other predictors differed, in particular symp-
toms (fever) and metabolic derangements, consistent with 
deaths from unknown causes not being primarily due to un-
diagnosed cryptococcosis, and at least some being due to SBIs 
and/or other undiagnosed infections such as tuberculosis and 
atypical mycobacteria. Finally, the severity of immunodefi-
ciency, timing of highest incidence of fatal and nonfatal events, 
and observed virological responses to ART raise the possibility 
that a substantial number of events may have been caused or 
exacerbated by IRIS. We found significant reductions in IRIS-
compatible events overall with enhanced prophylaxis. A  key 
limitation is that we were unable to use published definitions 
of IRIS [11, 12], and some IRIS events may have been misclas-
sified, due to paucity of clinical, radiological, and/or microbio-
logical supporting information (reflecting available services at 
the centers). Moreover, VL was only measured retrospectively, 
so not available contemporaneously; the earliest CD4 was week 
4 and not available for events before this. However, the ERC 
made all adjudications blinded to trial drugs, minimizing the 
potential for bias in comparisons of randomized groups. Our 
rates of IRIS were lower than some previous studies [16], par-
ticularly given the substantial immunosuppression at ART ini-
tiation, but likely included the majority of clinically important 
events, with missed events likely predominantly being less se-
vere. Antimicrobials may modulate the inflammatory milieu 
through reductions in subclinical infections, enteropathy, and 
microbial translocation, or through direct immunomodulatory 
effects (especially azithromycin), and it is well recognized that 
inflammation can drive mortality independent of immuno-
suppression [17–19]. Over the longer term, morbidity became 
more dominated by noninfectious events with lower fatality; 
however, these were also common early after ART, highlight-
ing the potential role of inflammation in noninfectious disease 
processes. Planned analysis of cryptococcal antigen, bacterial 
DNA, and inflammatory markers using pre-ART plasma sam-
ples will test these hypotheses and help inform the optimal 
choice of antimicrobials for future use.
Of note, 62.7% of participants had no serious morbidity/
mortality during their first 48 weeks on ART, despite very low 
pre-ART CD4 and high VL. Nevertheless, their low CD4 put 
them at substantially increased risk of impaired short- and 
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long-term immunological response, reinforcing the import-
ance of undertaking baseline CD4 to identify these patients. 
Where CD4 is becoming less available, our data reinforce the 
need to further develop CD4 point-of-care tests which at least 
qualitatively identify the most immunosuppressed individuals. 
Alternatively, total lymphocyte counts could be used to identify 
at least some of those at greatest risk [20, 21].
Given current WHO guidance focusing on diagnostic tools 
to rule out opportunistic infections before ART initiation [14], 
our pragmatic approach of clinically ruling out infections, fol-
lowed by an immediate prophylaxis bundle at ART initiation, 
may have substantial advantages for patients, staff, and pro-
grams. It can be implemented without diagnostic tests being 
available (especially at lower-level health centers) and more 
reliably ensure that patients start ART on time and have rapid 
prophylactic cover against the main infections. However, even 
the enhanced prophylaxis group experienced considerable early 
mortality. The most common cause of death was unknown; 
many occurred at home. This emphasizes the need to main-
tain close contact with immunosuppressed patients starting 
ART (even if clinically asymptomatic), ensuring they seek ur-
gent medical care if they develop new symptoms. New tools to 
identify those at greatest risk of death [22], and clinical trials to 
evaluate other short-term anti-inflammatory interventions in 
addition to ART, are also needed.
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